LOTTE Biologics is a global contract development and manufacturing organization delivering integrated biologics and bioconjugate services across the full product lifecycle.

With a unified Dual Hub Service model spanning the United States and South Korea, we strengthen supply chain security, enable scalable manufacturing pathways, and uphold consistent quality across regions.

Our capabilities encompass phase-appropriate drug substance manufacturing for mammalian-cell-based biologics, including monoclonal antibodies, fusion proteins, and multispecific modalities, as well as fully integrated Antibody-Drug Conjugate (ADC) manufacturing supported by strategic investment in onsite conjugation facilities.

Guided by the vision “Possibilities Beyond Limits,” LOTTE Biologics is committed to serving as a long-term, trusted leading global CDMO partner, supporting efficient scale-up, dependable manufacturing execution, and the continuous advancement of clients’ therapeutic programs.